SIFI’s Parasitic Eye Infection Drug & Biosimilar Aflibercept Among Raft Of EU Filings
Long-Acting Injectable Aripiprazole Could Improve Schizophrenia Drug Adherence
Polyhexanide, from SIFI, could become the first approved treatment for acanthamoeba keratitis, while aflibercept could become the first biosimilar version of Eylea in the EU.
You may also be interested in...
Pharming’s leniolisib for treating the rare immunodeficiency APDS is among the new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.
Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.
Fresenius Kabi’s tocilizumab biosimilar candidate is among the latest medicines that have been submitted for review for potential pan-EU approval.